Maravai Lifesciences Holdings Stock Earnings Reports

Maravai reported a strong start to 2026: Q1 revenue of $65.8M (41% YoY) with base business growth of 10% excluding COVID-related CleanCap. TriLink was the primary driver, up 65% YoY (15% base growth ex-CleanCap) and representing 72% of revenue; Cygnus grew modestly and remains highly profitable (73.8% adjusted EBITDA margin). Adjusted gross margin was 65.3% and adjusted EBITDA was $20.3M. The company generated $4.2M of positive free cash flow (first positive quarter since Q3 2024) and reduced debt with a $50M voluntary prepayment. Management raised full-year revenue guidance to $205M–$215M and substantially increased adjusted EBITDA guidance to $30M–$32M, citing favorable mix (more GMP and higher-margin discovery consumables), embedded restructuring savings (now expected to exceed $65M of annual EBITDA savings), and improved commercial execution (more annual/multi-quarter POs and stronger e-commerce). Key growth drivers highlighted: continued adoption of ModTail (70+ customers), launch of GMP-grade enzymes (GMP facility completed; launch expected this quarter), momentum in GMP funnels (9 RUO→GMP conversions expected in 2026), and expansion of Cygnus assay and analytical services. Near-term headwinds/uncertainties: quarter-to-quarter lumpiness from large orders, distributor ordering timing in China causing Q1 softness there, and continued relative weakness in academic orders. Overall, management emphasizes durable demand, margin expansion, and positive free cash flow for the remainder of 2026.